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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.001PURPOSE: Mammography is the cornerstone of breast cancer (BC) evaluation. This report investigates whether
breast density (BD) and mammographic features of the tumor can provide information on both BC susceptibility
to chemotherapy and other clinicopathologic features of locally advanced BC (LA BC).
MATERIALS AND METHODS: We evaluated mammography films and clinicopathological information of
patients with LA BC who received neoadjuvant chemotherapy (NAC) followed by tumor resection at the Instituto
Nacional de Enfermedades Neopla´sicas (INEN) from 2000 to 2011.
RESULTS: We selected 494 LA BC cases. Most cases were at clinical tumor stage 4 (48.5%), node stage 1
(58.8%) and had high histologic grade (53.3%). BI-RADS 1, 2, 3, and 4 BD were found in 16.9%, 22%,
35.7% and 25.1% of patients, respectively. High BD has been associated with younger age (p < 0.001), obesity
(p = 0.017) and no skin infiltration (T3 vs T4) (p = 0.018). An association between dusty microcalcifications and
HER2 group, as well as between casting microcalcifications and TN BC group (p = 0.05) was found. NAC
included anthracyclines and taxanes in 422 (85.5%) cases. Miller–Payne pathologic responses 4 and 5 (pCR)
in the primary lesion and absence of axillary lymph nodes involvement were found in 15.3% of cases and were
associated with younger age (p < 0.001) and HG-3 lesions (p < 0.001), but not with mammographic images.
CONCLUSION: Mammographic features are associated with specific clinicopathological features of pre-NAC
BC lesions but do not predict pCR. The implications and biological reasons for these findings require further study.
KEYWORDS: Density; Neoadjuvant; Microcalcification; Breast; Pathologic; ResponseMammography is the standard test for breastcancer (BC) screening. Masses, architec-tural distortions, focal asymmetries and
microcalciﬁcations found in mammographic images
suggest a malignant lesion.1,2 Higher breast density
(BD) reﬂects a larger percentage of ﬁbrous and
glandular components in the breast and is demon-
strated to be a BC risk factor.3Tumor features such as TNM stage, histological
type and grade, hormone receptors and HER2 status,
tumor phenotype, and response to neoadjuvant che-
motherapy (NAC) have demonstrated an inﬂuence
on patient outcome.4,5 NAC is the standard treat-
ment for LA BC. It allows for the identiﬁcation of
chemo sensitive tumors, increased rates of conserva-
tive surgery and decreased recurrence rates (similar149
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to adjuvant chemotherapy). Some tumor factors such
as phenotype and host factors such as obesity can pre-
dict pathologic complete response (pCR) to NAC as
well as outcome.6
Some studies report that mammographic features
like tumor shape, microcalciﬁcations and BD are asso-
ciated with clinicopathological ﬁndings, including
patient outcome. However, no studies evaluating
these image features have been performed in an exclu-
sively LA BC population or have been correlated with
NAC response.1,3,7–9,17,18
The aim of this retrospective study is to determine
whether mammographic features can predict response
to NAC or can correlate with clinicopathological fea-
tures such as patient age, obesity, clinical stage, recep-
tor status, and tumor phenotype in Peruvian women
with LA BC.MATERIALS AND METHODS
Identiﬁcation of the study population included ﬁle
evaluation of every BC patient treated in our center
from 2000 to 2011. Selected BC cases were those
with LA BC (CS IIB–IIIC) who received NAC fol-
lowed by tumor resection and who had stored bilat-
eral mammography ﬁlms.
Information was obtained from patient ﬁles and
pathology reports. Tumor samples were reviewed by
the pathologist when relevant information was not
speciﬁed in the pathology report. Pathological vari-
ables included tumor clinical stage, histological type
and grade (HG), HER2 and hormone receptors.
Tumors were histologically classiﬁed following the
World Health Organization guidelines and graded
according to Elson and Ellis.
Tumor phenotypes regarding ER, PgR, HER2 sta-
tus and histological grade (HG) were determined as
follows: luminal A (ER and PgR-positive, HER2-neg-
ative, and HG1–2); luminal B (ER-positive and one
of the following features: HER2-positive or PgR-neg-
ative or HG3); HER2-enriched (ER and PgR-nega-
tive, and HER2-positive); TN (ER, PgR and
HER2-negative). Pathologic response was evaluated
through the Miller–Payne scale, and it was considered
pCR where lymph node involvement was absent,
and grade 4–5 responses were found in primary
lesions.
All mammography ﬁlms were reviewed for this
analysis by an INEN breast radiologist who bases
his expertise on having interpreted more than 5000
sets of screening images per year for more than ﬁve
years. He was blinded to clinical-pathological tumor
information.Breast density was reported according to the
Breast Imaging Reporting and Data System (BI-
RADS) as proposed by the American College of
Radiology, and as follows: BI-RADS I: the breast is
almost entirely fat; BI-RADS II: there are scattered
ﬁbro-glandular densities; BI-RADS III: the breast is
heterogeneously dense with interspersed fatty areas;
and BI-RADS IV: the breast tissue is uniformly
dense (Fig 1).10
The dominant mammographic feature was
recorded as mass, architectural distortion, or focal
asymmetry. The dominant feature was the most easily
perceived abnormality, not necessarily the one
that appeared most malignant. Tumor microcalciﬁca-
tions were classiﬁed according to Tabár in dusty,
crushed stone, distal calciﬁcation, and casting
(Fig 1).2
Data sets were combined to identify relationships
among mammographic appearance and breast
tumor features. The signiﬁcance of differences was
evaluated using the chi-square test. Additionally, we
performed a univariate analysis through a logistic
regression model in order to evaluate the association
between variables. Outcome was evaluated by
median of both overall survival (OS) and disease free
survival (DFS). A p value <0.05 was considered
signiﬁcant.RESULTS
Description of population features and
clinicopathologic associations
The study group consisted of 494 patients. Patients
fell within age range of 24–82 years with a mean of
49 years. Body mass index (BMI) analysis showed
that 29.5%, 39.6% and 30.9% of the patients belonged
to the underweight/normal, overweight and obese
class, respectively. Most cases were in clinical tumor
size stage 4 (48.5%) and in node stage 1 (58.8%).
Ductal histology represented 93.5% and grade III rep-
resented 53.3% of cases. Luminal A, luminal B,
HER2-enriched and TN BC groups represented
30.1%; 30.8%; 10.3%; and 28.9% of the patients,
respectively. Neoadjuvant chemotherapy included
anthracyclines and taxanes in 422 (85.5%) cases. No
patients received neo or adjuvant trastuzumab.
Miller–Payne pathological responses 4 and 5 in the
primary lesion and absence of disease in axillary
lymph nodes (pCR) were found in 15.3% (75) of
cases. DFS and OS median for the whole population
was 8.2 and 5.8 years, respectively. DFS were 78.5mo
in luminal A cases, 75.4mo in luminal B cases, 53.9mo
in HER2-enriched, and 62.1mo in TN BCHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
Figure 1. Mammographic features: Image 1 and 2 represent breast density grades 1 and 4, respectively. Images 3 and 4 represent tumor calcification belonging to casting
and dusty microcalcification, respectively.
MAMMOGRAPHIC FEATURES AND CHEMOTHERAPY original research report(p = 0.001). OS was 110.6mo in luminal A cases,
100.4mo in luminal B, 92.5mo in HER2- enriched
and 103.9mo in TN BC (p = 0.02). Additional clini-
copathological information of the study population is
described in Table 1.
pCR was associated with younger age, high histo-
logic grade and no luminal phenotype (17.8% in
HER2-enriched, 23% in TN BC and 10.5% in lumi-
nal cases) (p = 0.05), as well as with longer DFS
(p = 0.001) but no longer OS (p = 0.266)
(Table 3).Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014Association between BD and clinicopathologic
features
BD was classiﬁed as BI-RADS grades 1, 2, 3 and 4 in
16.9%, 22%, 35.7% and 25.1%, respectively. High BD
(BI-RADS 3 and 4) has been associated with younger
age (<45 vs >45 years) (p < 0.001). It has also been
associated with obesity (IBM >29) versus under-
weight/normal (IBM< 25) (p = 0.012) and to higher
rates of cT3 over cT4 (p = 0.018) (Table 2).
A relationship between BD and achievement of
pCR after NAC has also been evaluated. However,151
Table 1. Clinicopathological features of population.
Variable No. of patients %
Total 494
Age (years)
Median (range) 49 (24–82)
Weight
Underweight/normal 145 29.5
Overweight 195 39.6
Obese 152 30.9
Clinical stage
cT1–2 63 12.8
cT3 190 38.7
cT4 238 48.5
cN0 97 19.7
cN1 290 58.8
cN2–N3 106 21.5
Histological type
Ductal 461 93.5
Lobular 21 4.3
Others 11 2.2
Histological grade
GH-I–II 222 46.7
HG-III 253 53.3
Molecular sub-type
Luminal A 132 30.1
Luminal B 135 30.8
HER2-enriched 45 10.3
TN 127 28.9
Neoadjuvant chemotherapy
Anthracyclines w/o Taxanes 61 12.2
Anthracyclines w/ Taxanes 422 85.5
Others 11 2.3
Pathologic response
pCR (M&P:4–5 NA/ND) 75 15.3
Non-pCR 416 84.7
Median survival (years)
DFS 8.2 –
OS 5.8 –
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univariate analysis did not ﬁnd differences (p = 0.55)
(Table 2). No association with outcome was found
(Table 2).
Association between mammographic characteristics
of tumor and clinicopathologic features
The dominant mammographic feature was recorded
as mass (n = 358) (108 with rounded shape) or archi-
tectural distortion (n = 19). Triple negative pheno-
type, undifferentiated cancer (HG-III), absence of
in situ component and pCR were associated with
rounded mass.
Microcalciﬁcation was found in 111 cases (31%)
and was linked to the presence of in situ carcinoma
component (p < 0.001), but not to pathologic
response to NAC (p = 0.305) or to outcome
(p = 0.23). When we evaluated the speciﬁc shape of
microcalciﬁcations, we found dusty, crushed stone,
distal calciﬁcation, and casting microcalciﬁcations in
49 (44.1%), 5 (4.5%), 5 (4.5%) and 52 (46.8%) cases,
respectively. When we evaluated the non-luminal sub-
types, we found that dusty calciﬁcation tended to be
more frequent between HER2-enriched than TN
lesions (28% vs 10.2%) and casting features were more
frequent between TN than HER2-enriched lesions
(34.8% vs 6.5%; p = 0.05). No speciﬁc shape was
more prevalent in the luminal group, and no shape
had a predilection for either of the luminal subgroups
(Table 3).DISCUSSION
Evidence indicates that BC behavior, treatment
response and outcome of patients are inﬂuenced not
only by tumor features, but also by host factors.3
Breast density is a host factor inﬂuenced by estro-
gen level in serum. Estrogen concentration of this hor-
mone is considered a carcinogen for BC and depends
on body mass index (adipose tissue is the primary
source of estrogen in postmenopausal women). Age
is also a host factor (the ovary being the primary
source of estrogen in premenopausal women), as are
previous history of hormone treatment and reproduc-
tive factors. Similarly, our data ﬁnds that the rate of
high BD in our Peruvian BC cases is comparable to
the rates that have previously been described in other
races, and that BD is signiﬁcantly linked to host
metabolism factors like young age and obesity.11,14
Additionally, some studies have reported a relation-
ship between BD and serum levels of non-hormonal
carcinogenic factors like IGF1 and prolactin.12,13Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
Table 2. Relationship between breast density and clinicopathological features.
Variables Breast density (BIRADS) p
1: n = 83 (16.9%) 2: n = 108 (22%) 3: n = 175 (35.7%) 4: n = 123 (25.1%)
Age (years) <0.001
Age <46 8 (9.8) 21 (19.4) 64 (36.8) 71 (57.7)
Age >45 74 (90.2) 87 (80.6) 110 (63.2) 52 (42.3)
Weight 0.017
Underweight/normal (<25) 14 (16.9) 35 (32.7) 48 (27.7) 46 (37.4)
Overweight (25–29) 30 (36.1) 39 (36.4) 74 (42.8) 51 (41.5)
Obese (BMI >29) 39 (46.9) 34 (31.8) 53 (30.6) 24 (19.5)
Histological type 0.395
Ductal 76 (91.6) 99 (92.5) 163 (94.2) 118 (95.9)
Lobular 4 (4.8) 6 (5.6) 8 (4.6) 3 (2.4)
Others 3 3 4 2
Histological grade 0.475
HG-I–II 34 (40.6) 47 (43.9) 85 (49.1) 54 (43.9)
HG-III 44 (53) 55 (51.4) 85 (49.1) 66 (53.7)
T stage 0.018
cT1–T2 9 (10.8) 18 (17.0) 24 (13.8) 10 (8.1)
cT3 23 (27.7) 36 (34.0) 77 (44.3) 54 (43.9)
cT4 51 (61.4) 52 (49.1) 73 (42.0) 59 (48.0)
N stage 0.933
cN0 13 (15.7) 23 (21.5) 40 (23.1) 17 (13.8)
cN1 50 (60) 62 (57.9) 107 (61.9) 70 (56.9)
cN2–N3 20 (24.1) 23 (21.5) 27 (15.6) 36 (29.2)
Molecular sub-type 0.991
Luminal A 25 (30) 25 (23.4) 50 (28.9) 30 (24.4)
Luminal B 22 (26.5) 32 (29.9) 42 (24.3) 38 (30.9)
HER2-enriched 6 (7.2) 12 (11.2) 13 (7.5) 14 (11.4)
TN 22 (26.5) 28 (26.2) 48 (27.8) 27 (21.9)
Pathologic response 0.550
No pCR 70 (84.3) 93 (86.9) 144 (83.2) 104 (84.5)
pCR 13 (15.7) 14 (13.1) 29 (16.8) 19 (15.5)
Median survival (years)
DFS 5.8 6.2 5.6 5.5 0.314
OS 8.7 8.3 8.8 8.7 0.933
MAMMOGRAPHIC FEATURES AND CHEMOTHERAPY original research reportThese factors could modulate tumor and breast tissue
microenvironment features to induce a speciﬁc cancer
behavior.Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014Studies with small samples have suggested an asso-
ciation between BD and receptor status of tumor.7,9
However, Phipps et al. evaluated the mammographies153
Table 3. Relationship between mammographic and clinicopathologic features of cancer lesions.
Clinicopathologic
features
Mammographic features p
Shape: Microcalcification:
Mass with rounded
shape (n = 108)
Mass without rounded
shape (n = 250)
Architecture
distortion (n = 19)
p No
microcalcification
(n = 247)
With microcalcification
Dusty
(n = 49)
Crushed
Stone (n = 5)
Distal
calcification
(n = 5)
Casting
(n = 52)
Tumor phenotype
Luminal A 22 (23.9) 81 (36.3) 5 (29.4) 0.019 78 (35.9) 12 (30.7) 2 (40) 2 (50) 9 (19.6) 0.905
Luminal B 29 (31.5) 72 (32.2) 5 (29.4) 63 (29) 16 (41) 3 (60) 1 (25) 18 (39.1)
HER2-enriched 7 (7.6) 23 (10.3) 4 (23.5) 15 (6.9) 11 (28) 0 1 (25) 3 (6.5)
TN 34 (36.9) 47 (21) 3 (17.6) 61 (28.1) 4 (10.2) 0 0 16 (34.8)
Unknown 16 27 2 30 6 – 1 6
In situ component
Absent 78 (76.5) 122 (50.8) 10 (52.6) <0.001 152 (65.2) 20 (41.6) 3 (60) 2 (40) 27 (49.0) <0.001
Present 24 (23.5) 118 (49.2) 9 (47.4) 81 (34.8) 28 (58.3) 2 (40) 3 (60) 28 (51.0)
Unknown 6 10 – 14 1 – – 1
Histologic grade (HG)
HG I–II 36 (34.2) 128 (53.6) 11 (57.9) 0.001 113 (47.7) 23 (47.9) 4 (80) 4 (80) 20 (40.8) 0.998
HG III 69 (65.8) 111 (46.4) 8 (42.1) 124 (58.3) 25 (52.1) 1 (20) 1 (20) 29 (59.2)
Unknown 3 11 – 10 1 – – 3
Age
<45 years 42 (38.9) 86 (34.5) 5 (26.3) 0.431 91 (36.8) 18 (36.7) 1 (20) 1 (20) 17 (33.3) 0.56
>45 years 66 (61.1) 163 (65.5) 14 (73.7) 156 (63.2) 31 (63.3) 4 (80) 4 (80) 34 (66.7)
Unknown – 1 – – – – – 1
Pathological response
No pCR 85 (78.7) 216 (86.7) 15 (78.9) 0.055 205 (82.9) 44 (89.8) 4 (80) 3 (60) 45 (88.2) 0.305
pCR 23 (29.1) 33 (13.3) 4 (21.1) 42 (17.1) 5 (10.2) 1 (20) 2 (40) 6 (11.8)
Unknown – 1 – – – – – 1
DFS (at 3 years) 69.2 67.8 49.2 0.200 70.8 65.6 NE NE 61.8 0.23
OS (at 3 years) 96.3 96.1 0.9 0.970 95.6 97 NE NE 95.5 0.82
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quently diagnosed with BC) included in the Breast
Cancer Surveillance Consortium and found that BD
was associated with higher risk for the development
of all subtypes of BC without predisposition for
tumor phenotype or other clinicopathological
feature.3 Similarly, we did not ﬁnd a signiﬁcantassociation between density of contralateral breast
and clinicopathological features of the tumor. We
found that cancer involvement in skin was more
frequent in low BD, a fact not previously
described but that could represent stroma
differences to allow tumor inﬁltration to contiguous
skin.Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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Although analysis of factors inﬂuencing pCR rates
did not ﬁnd an association with BD, we conﬁrmed
that clinicopathological factors such as high histolog-
ical grade (a tumor factor) and younger age (a host
factor) correlate with pathological response. There-
fore, it appears that differences in breast microenvi-
ronment associated with BD do not produce a
strong inﬂuence over antineoplastic activity of chemo-
therapy. However, we need to evaluate this statement
in prospective studies. We also conﬁrmed that
response to NAC is a surrogate marker of overall sur-
vival in BC patients.15
Mammographic features of breast tumors have also
been extensively studied and with some studies have
ﬁnding found an association between image shape
and pathologic characteristics.1,16–18 Although we
did not ﬁnd links among tumor phenotypes, we found
an association between the rounded shape of a tumor,
all presence of an in situ component, well-differenti-
ated lesions, and absence of pCR.
Microcalciﬁcations are extensively studied mam-
mographic features. They are found in 40% of BCs
and their features can take us closer to the cancer
diagnostic.18 They usually consist of carbonated cal-
cium hydroxyapatite and their development appears
to be a cell-speciﬁc regulated process that inﬂuences
tumor behavior.19 Our microcalciﬁcation prevalence
(31.1%) is in the published range and is associated
with the presence of an in situ component
(p < 0.001). Some series have found an association
between microcalciﬁcation and all high-grade histol-
ogy, non-TN phenotype and a poor outcome in spe-
ciﬁc subsets. However, we did not ﬁnd this
association in our population of locally advanced
tumors.16,17
The evaluation of association between speciﬁc
microcalciﬁcation shapes (according to the TabárHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014description 2) and tumor pathologic features showed
an association between dusty microcalciﬁcation and
HER2-enriched group as well as between the casting
microcalciﬁcations and the TN BC group (p = 0.05).
Despite the small number of evaluated cases with mic-
rocalciﬁcations, our data conﬁrms the theory, for the
ﬁrst time, that calcium deposits inside the tumor
can inﬂuence its behavior.
Unfortunately, our analysis has some limitations,
including the use of different chemotherapy regimens
due to changes in standard treatments over the 11
evaluated years. Similarly, administered doses are dis-
similar as clinician decisions are based on patient
comorbidities. Tumors progressing during NAC that
did not go to surgery have been excluded. However, a
strong point of the present analysis is the uniform
assessment of pathologic response by the Institute
pathologists as well as the uniform mammography
evaluation by the Institute radiologist.CONCLUSION
Mammography features are associated with clinico-
pathological features in BC. We found that high
BD is linked to the absence of tumoral skin inﬁltra-
tion. We also found that rounded shape was associ-
ated with TN phenotype; and dusty and casting
calciﬁcations were associated with HER2 group and
TN BC group, respectively. This information needs
to be tested in larger series and more studies are
required to understand the associated biological bases.CONFLICT OF INTEREST
No conﬂict of interestREFERENCES1. Thurfjell E, Thurfjell MG, Lindgren A. Mammo-
graphic finding as predictor of survival in 1–9 mm
invasive breast cancers. Worse prognosis for cases
presenting as calcifications alone. Breast Cancer
Res Treat 2001;67(2):177–80.
2. Tabr Lszl, Tot Tibor, Dean Peter B. Casting
type calcifications: sign of a subtype with deceptive
features (breast cancer – early detection with
mammography). 1st Edition. New York: Thieme.
Stuttgart; 2007.
3. Phipps AI, Buist DS, Malone KE, Barlow WE,
Porter PL, Kerlikowske K, et al. Breast density, body
mass index, and risk of tumor marker-defined
subtypes of breast cancer. Ann Epidemiol
2012;22(5):340–8.
4. Castaneda CA, Andrs E, Barcena C, Gmez HL,
Corts-Funs H, Ciruelos E. Behaviour of breastcancer molecular subtypes through tumour progres-
sion. Clin Transl Oncol 2012;14(6):481–5.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M,
Jeffrey SS, Rees CA, et al. Molecular portraits of
human breast tumours. Nature
2000;406(6797):747–52.
6. Litton JK, Gonzalez-Angulo AM, Warneke CL,
Buzdar AU, Kau SW, Bondy M, et al. Relationship
between obesity and pathologic response to neo-
adjuvant chemotherapy among women with opera-
ble breast cancer. J Clin Oncol 2008;26(25):4072–7.
7. Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ,
Rosner B, Vachon C, et al. Mammographic breast
density and subsequent risk of breast cancer in
postmenopausal women according to tumor
characteristics. J Natl Cancer Inst
2011;103(15):1179–89.8. Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung
TH, Chen LS, et al. Mammographic tumor features
can predict long-term outcomes reliably in women
with 1-14-mm invasive breast carcinoma. Cancer
2004;101(8):1745–59.
9. Ding J, Warren R, Girling A, Thompson D, Easton
D. Mammographic density, estrogen receptor status
and other breast cancer tumor characteristics.
Breast J 2010;16(3):279–89.
10. ACR breast imaging reporting and data system
atlas. BI-RADS atlas. 4th edition. Reston;
VA: American College of, Radiology; 2003.
11. Vachon CM, Kuni CC, Anderson K, Anderson VE,
Sellers TA. Association of mammographically
defined percent breast density with epidemiologic
risk factors for breast cancer (United States). Cancer
Causes Control 2000;11(7):653–62.155
156
original research report MAMMOGRAPHIC FEATURES AND CHEMOTHERAPY
12. Boyd NF, Martin LJ, Yaffe MJ, Minkin S.
Mammographic density and breast cancer risk:
current understanding and future prospects. Breast
Cancer Res 2011;13(6):223.
13. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E,
Yaffe M, et al. The association of breast mitogens
with mammographic densities. Br J Cancer
2002;87(8):876–82.
14. Checka CM, Chun JE, Schnabel FR, Lee J, Toth
H. The relationship of mammographic density and
age: implications for breast cancer screening. AJR
Am J Roentgenol 2012;198(3):W292–5.
15. von Minckwitz G, Untch M, Blohmer JU, Costa
SD, Eidtmann H, Fasching PA, et al. Definition andimpact of pathologic complete response on progno-
sis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol
2012;30(15):1796–804.
16. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee
SA. Triple-negative breast cancer: correlation
between imaging and pathological findings. Eur
Radiol 2010;20(5):1111–7.
17. Ling H, Liu ZB, Xu LH, Xu XL, Liu GY, Shao ZM.
Malignant calcification is an important unfavorable
prognostic factor in primary invasive breast cancer.
Asia Pac J Clin Oncol 2013;9(2):139–45.
18. Fondrinier E, Lorimier G, Guerin-Boblet V,
Bertrand AF, Mayras C, Dauver N. Breast microcal-Hemacifications: multivariate analysis of radiologic and
clinical factors for carcinoma. World J Surg
2002;26(3):290–6.
19. Cox RF, Hernandez-Santana A, Ramdass S,
McMahon G, Harmey JH, Morgan MP. Microcalci-
fications in breast cancer: novel insights into the
molecular mechanism and functional consequence
of mammary mineralisation. Br J Cancer
2012;106(3):525–37.tol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
